{"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}],"groups":[{"description":"GVAX vaccine\n\nParticipants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD.\n\nConditioning regimen: In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 4 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.\n\nAllogeneic Hematopoietic Stem Cell Transplant: Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor.\n\nGVHD Prevention:\n\n* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.\n* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.\n\nGVAX: GVAX vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria.","id":"BG000","title":"GVAX"},{"description":"Placebo\n\nParticipants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD.\n\nConditioning regimen: In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 4 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.\n\nAllogeneic Hematopoietic Stem Cell Transplant: Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor.\n\nGVHD Prevention:\n\n* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.\n* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.\n\nPlacebo: Placebo vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"75","value":"64"},{"groupId":"BG001","lowerLimit":"35","upperLimit":"74","value":"63"},{"groupId":"BG002","lowerLimit":"27","upperLimit":"75","value":"63"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"34"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"53"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"19","upperLimit":"67","value":"28"},{"groupId":"BG001","lowerLimit":"19","upperLimit":"68","value":"30"},{"groupId":"BG002","lowerLimit":"19","upperLimit":"68","value":"28"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Donor Age","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}],"title":"ECOG 0-Fully active; no performance restrictions."},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"33"}],"title":"ECOG 1-Strenuous physical activity restricted; fully ambulatory and able to carry out light work."},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}],"title":"ECOG 2-Capable of all self-care but unable to carry out any work activity Up and about >50% of time"}],"denoms":[{"counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ECOG Score at baseline was not available for one participant","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}],"title":"Female Donor"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"40"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}],"title":"Male Donor"}],"paramType":"NUMBER","title":"Donor Sex","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"NUMBER","title":"Male Recipient With female Donor","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}],"title":"Acute Myeloid Leukemia"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"title":"Myelodysplastic Syndrome"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Transplanted","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"2nd Complete Remission-Leukemia returned after a remission and there are now no signs of disease"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}],"title":"Induction Failure-Leukemia has not gone away and not responded to 2 cycles of chemotherapy"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}],"title":"Relapsed- Leukemia has returned after a period of remission"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Untreated- Leukemia has never been treated"}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients with AML analyzed.","title":"Acute Myeloid Leukemia Disease Status At Transplantation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Favorable (Best Risk)"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}],"title":"Intermediate (Middle Risk)"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}],"title":"Adverse (Worst Risk)"}],"denoms":[{"counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}],"units":"Participants"}]}],"description":"System used to provide prognostic information in AML based on identified genetic abnormalities. Scale is from favorable to intermediate to adverse.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients with AML analyzed","title":"AML European Leukemia Net (ELN) Risk Stratification","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Treatment Related MDS- MDS arising from cytotoxic therapy given for a prior condition"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"29"}],"title":"Non-Treatment Related MDS- Disease which has arisen with no apparent cause"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients with MDS analyzed","title":"Myelodysplastic Syndrome Type at Transplant","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}],"title":"Good"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"Intermediate"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Poor"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}],"title":"Very Poor"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"units":"Participants"}]}],"description":"System used to assess the prognosis of patients with myelodysplastic syndromes. With scale of Very good to Very Poor.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients with MDS analyzed","title":"MDS Revised International Prognostic Scoring System Risk at Transplant","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"24"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Not Done"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"units":"Participants"}]}],"description":"Tumor protein 53 TP53 defects influence adversely the MDS clinical outcome and the treatment response rate. Subjects were evaluated for mutations in this gene to help determine prognosis","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients with MDS analyzed","title":"MDS TP53 Mutated","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"47"}],"title":"Yes"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Cytoreductive therapy before HSCT","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"4","upperLimit":"60","value":"13"},{"groupId":"BG001","lowerLimit":"4","upperLimit":"58","value":"11"},{"groupId":"BG002","lowerLimit":"4","upperLimit":"60","value":"12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Marrow Blasts at enrollment","unitOfMeasure":"Percent of participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"42"}],"title":"Matched Unrelated"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}],"title":"Matched Sibling"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Donor Type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}],"title":"Recipient +/ Donor +"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}],"title":"Recipient +/ Donor -"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}],"title":"Recipient -/ Donor +"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"23"}],"title":"Recipient -/ Donor -"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"description":"Cytomegalovirus infection is a risk in this population. Prior exposure of the stem cell donor and recipient is important in determining prognosis","paramType":"COUNT_OF_PARTICIPANTS","title":"Cytomegalovirus (CMV) Serology Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"30"}],"title":"Myeloablative Conditioning Busulfan 4 days/Fludarabine"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"27"}],"title":"Reduced Intensity Conditioning Busulfan 2 days/Fludarabine"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Conditioning Regimen","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Bone Marrow"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"53"}],"title":"Peripheral Blood"}],"denoms":[{"counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"57"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Graft Source","unitOfMeasure":"Participants"}],"populationDescription":"Baseline Analysis Population only includes participants who received at least 1 GVAX or placebo vaccine"}